Journal of Bioanalysis & Biomedicine

5^th European Biosimilars Congress

June 27-29, 2016 Valencia, Spain

Scientific Tracks Abstracts

• Supporting biosimilar clinical trials in the UK

  Sarah Cooper

  PDF HTML

• The emergence of orphan biosimilars

  Triona Bolger, Paul Zhang, Varun Renjen, Brian Sattin, Anny Lin and Aditya Venugopal

  PDF HTML

• The importance of IP protection and SPCs for biologics and biosimilar products

  Luder Behrens

  PDF HTML

• An update on the legal landscape for biosimilars in the USA

  Paul A Calvo

  PDF HTML

• Intellectual property issues in global biosimilar programs

  Christoph Volpers

  PDF HTML

• Dosing, double patenting and the US biosimilars landscape

  Nabeela Rasheed

  PDF HTML

• Biosimilar development cost: Role of analytics

  Dipti Gulati

  PDF HTML

• Pharmacovigilance in cancer medicine

  Luis H Camacho

  PDF HTML

• Raman spectroscopy as a real-time in situ analyzer for cell culture bioprocesses

  Alexander Pitters, Maryann Cuellar, Pat Wiegand, Sean Gilliam, Ian R Lewis and Bruno Lenain

  PDF HTML

• Analytical assessment of biosimilarity-Considerations in study design

  Christina Vessely

  PDF HTML

• Recommendations from the AAPS LBABFG biosimilars action program committee for the validation of pharmacokinetic and immunogenicity assays in support of biosimilar drug development

  Aparna Kasinath

  PDF HTML

• Impact on technology integration on better and faster biosimilars pipeline

  Christelle Dagoneau

  PDF HTML

• Biosimilar globalization-A silver lining in untested waters

  Candida Fratazzi

  PDF HTML

• From neuronal networks to neuromodulation with biosimilars

  Luis Ulloa

  PDF HTML

• High throughput assays for the determination of the potency and comparability of biosimilars and innovator products

  Michael G Tovey

  PDF HTML

• Growth potential of biosimilar products in Bangladesh

  Md Abu Zafor Sadek

  PDF HTML